Identification of the α 2 -δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Neuropathic pain is a debilitating condition affecting millions of people around the world and is defined as pain that follows a lesion or dysfunction of the nervous system. This type of pain is difficult to treat, but the novel compounds pregabalin (Lyrica) and gabapentin (Neurontin) have proven clinical efficacy. Unlike traditional analgesics such as nonsteroidal antiinflammatory drugs or narcotics, these agents have no frank antiinflammatory actions and no effect on physiological pain. Although extensive preclinical studies have led to a number of suggestions, until recently their mechanism of action has not been clearly defined. Here, we describe studies on the analgesic effects of pregabalin in a mutant mouse containing a single-point mutation within the gene encoding a specific auxiliary subunit protein (α 2 -δ-1) of voltage-dependent calcium channels. The mice demonstrate normal pain phenotypes and typical responses to other analgesic drugs. We show that the mutation leads to a significant reduction in the binding affinity of pregabalin in the brain and spinal cord and the loss of its analgesic efficacy. These studies show conclusively that the analgesic actions of pregabalin are mediated through the α 2 -δ-1 subunit of voltage-gated calcium channels and establish this subunit as a therapeutic target for pain control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
FACS-optimized mutants of the green fluorescent protein (GFP)
Cormack, B. P., Valdivia, R. H., & Falkow, S. (1996) · Gene · doi:10.1016/0378-1119(95)00685-0 · Cited by 2,620
The formalin test: an evaluation of the method
Tjølsen, A., Berge, O.-G., Hunskaar, S., Rosland, J. H., & Hole, K. (1992) · Pain · doi:10.1016/0304-3959(92)90003-t · Cited by 2,428
Structure and Regulation of Voltage-Gated Ca 2+ Channels
Catterall, W. A. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.521 · Cited by 2,344
The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium Channel
Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., & Woodruff, G. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5768 · Cited by 1,181
Self-citationA summary of mechanistic hypotheses of gabapentin pharmacology
Taylor, C. P., Gee, N. S., Su, T.-Z., Kocsis, J. D., Welty, D. F., Brown, J. P., Dooley, D. J., Boden, P., & Singh, L. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(97)00084-3 · Cited by 774
Self-citationPregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial
Dworkin, R. H., Corbin, A. E., Young, J. P., Sharma, U., LaMoreaux, L., Bockbrader, H., Garofalo, E. A., & Poole, R. M. (2003) · Neurology · doi:10.1212/01.wnl.0000055433.55136.55 · Cited by 768
Luo, Z. D., Chaplan, S. R., Higuera, E. S., Sorkin, L. S., Stauderman, K. A., Williams, M. E., & Yaksh, T. L. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-06-01868.2001 · Cited by 616
Auxiliary subunits: essential components of the voltage-gated calcium channel complex
Arikkath, J., & Campbell, K. P. (2003) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(03)00066-7 · Cited by 505
Treatment of Social Phobia With Gabapentin: A Placebo-Controlled Study
Pande, A. C., Davidson, J. R. T., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., Greist, J. H., & Sutherland, S. M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00010 · Cited by 395
Cited by
Zamponi, G. W., Striessnig, J., Koschak, A., & Dolphin, A. C. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009654 · Cited by 1,103
Self-citationNociceptors—Noxious Stimulus Detectors
Woolf, C. J., & Ma, Q. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.016 · Cited by 1,048
Eroglu, Ç., Allen, N. J., Susman, M. W., O'Rourke, N. A., Park, C. Y., Özkan, E., Chakraborty, C., Mulinyawe, S. B., Annis, D. S., Huberman, A. D., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.025 · Cited by 893
A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11536200-000000000-00000 · Cited by 690
Taylor, C. P., Angelotti, T., & Fauman, E. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.09.008 · Cited by 565
Gilron, I., Bailey, J. M., Tu, D., Holden, R. R., Jackson, A. C., & Houlden, R. L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61081-3 · Cited by 500
Clarke, H., Bonin, R. P., Orser, B. A., Englesakis, M., Wijeysundera, D. N., & Katz, J. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318249d36e · Cited by 481
Buvanendran, A., Kroin, J. S., Della Valle, C. J., Kari, M., Moric, M., & Tuman, K. J. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181c4273a · Cited by 460
Bauer, C. S., Nieto-Rostro, M., Rahman, W., Tran-Van-Minh, A., Ferron, L., Douglas, L., Kadurin, I., Sri Ranjan, Y., Fernandez-Alacid, L., Millar, N. S., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0356-09.2009 · Cited by 421
Self-citationPharmacological disruption of calcium channel trafficking by the α 2 δ ligand gabapentin
Hendrich, J., Van Minh, A. T., Heblich, F., Nieto-Rostro, M., Watschinger, K., Striessnig, J., Wratten, J., Davies, A., & Dolphin, A. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708930105 · Cited by 417
Self-citationEtiology and Pharmacology of Neuropathic Pain
Alles, S. R. A., & Smith, P. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014399 · Cited by 395
An overview of treatment approaches for chronic pain management
Hylands-White, N., Duarte, R. V., & Raphael, J. H. (2017) · Rheumatology International · doi:10.1007/s00296-016-3481-8 · Cited by 387
Ca2+ channel α2δ ligands: novel modulators of neurotransmission
Dooley, D. J., Taylor, C. P., Donevan, S., & Feltner, D. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.12.006 · Cited by 387
Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments
Gambeta, E., Chichorro, J. G., & Zamponi, G. W. (2020) · Molecular Pain · doi:10.1177/1744806920901890 · Cited by 376
Calcium channel auxiliary α2δ and β subunits: trafficking and one step beyond
Dolphin, A. C. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3311 · Cited by 368
Self-citationThe β Subunit of Voltage-Gated Ca2+Channels
Buraei, Z., & Yang, J. (2010) · Physiological Reviews · doi:10.1152/physrev.00057.2009 · Cited by 367
Functional biology of the α2δ subunits of voltage-gated calcium channels
Davies, A., Hendrich, J., Van Minh, A. T., Wratten, J., Douglas, L., & Dolphin, A. C. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.03.005 · Cited by 360
Self-citationα2δ expression sets presynaptic calcium channel abundance and release probability
Hoppa, M. B., Lana, B., Margas, W., Dolphin, A. C., & Ryan, T. A. (2012) · Nature · doi:10.1038/nature11033 · Cited by 358
Self-citationZiconotide for treatment of severe chronic pain
Schmidtko, A., Lötsch, J., Freynhagen, R., & Geisslinger, G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60354-6 · Cited by 356
Dolphin, A. C. (2016) · The Journal of Physiology · doi:10.1113/jp272262 · Cited by 352
Self-citationPregabalin: Its Pharmacology and Use in Pain Management
Gajraj, N. M. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000287643.13410.5e · Cited by 343
Calcium-Permeable Ion Channels in Pain Signaling
Bourinet, E., Altier, C., Hildebrand, M. E., Trang, T., Salter, M. W., & Zamponi, G. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00023.2013 · Cited by 337
Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet
Rogawski, M. A., Löscher, W., & Rho, J. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022780 · Cited by 336
Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights
Kremer, M., Salvat, E., Muller, A., Yalcin, I., & Barrot, M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.057 · Cited by 312
Neely, G. G., Hess, A., Costigan, M., Keene, A. C., Goulas, S., Langeslag, M., Griffin, R. S., Belfer, I., Dai, F., Smith, S. B., et al. (2010) · Cell · doi:10.1016/j.cell.2010.09.047 · Cited by 307
Neuropathic Pain: Mechanism-Based Therapeutics
Bannister, K., Sachau, J., Baron, R., & Dickenson, A. H. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021524 · Cited by 302
Implications and mechanism of action of gabapentin in neuropathic pain
Kukkar, A., Bali, A., Singh, N., & Jaggi, A. S. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0057-y · Cited by 301
Chen, J., Li, L., Chen, S.-R., Chen, H., Xie, J.-D., Sirrieh, R. E., MacLean, D. M., Zhang, Y., Zhou, M.-H., Jayaraman, V., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.021 · Cited by 283
Arnold, L. M., Russell, I. J., Diri, E. W., Duan, W. R., Young, J. P., Sharma, U., Martin, S. A., Barrett, J. A., & Haig, G. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.03.013 · Cited by 277
Stahl, S. M., Porreca, F., Taylor, C. P., Cheung, R., Thorpe, A. J., & Clair, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.001 · Cited by 277
Mechanisms of the gabapentinoids and α2δ‐1 calcium channel subunit in neuropathic pain
Patel, R., & Dickenson, A. H. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.205 · Cited by 277
Mechanisms of analgesia by gabapentin and pregabalin – Calcium channel α2-δ [Cavα2-δ] ligands
Taylor, C. P. (2009) · Pain · doi:10.1016/j.pain.2008.11.019 · Cited by 257
Crofford, L. J., Mease, P. J., Simpson, S. L., Young, J. P., Martin, S. A., Haig, G. M., & Sharma, U. (2008) · Pain · doi:10.1016/j.pain.2008.02.027 · Cited by 236
Prolonged Gabapentin Analgesia in an Experimental Mouse Model of Fibromyalgia
Nishiyori, M., & Ueda, H. (2008) · Molecular Pain · doi:10.1186/1744-8069-4-52 · Cited by 176
Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins
Maher, M. P., Matta, J. A., Gu, S., Seierstad, M., & Bredt, D. S. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.001 · Cited by 64
Pregabalin: A Review of its Use in Fibromyalgia
Lyseng-Williamson, K. A., & Siddiqui, M. A. A. (2008) · Drugs · doi:10.2165/00003495-200868150-00009 · Cited by 50
Fibromyalgia: A complex syndrome requiring a multidisciplinary approach
Spaeth, M., & Briley, M. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1030 · Cited by 36
“This reduction in synaptic activity results in reduced neuronal excitability which is thought to explain its clinical activities (Dooley et al., 2007; Field et al., 2006; Taylor et al., 2007).”
BackgroundParsons, B., Emir, B., & Knapp, L. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000100 · Cited by 20
Putative roles of SLC7A5 (LAT1) transporter in pain
Alles, S. R. A., Gomez, K., Moutal, A., & Khanna, R. (2020) · Neurobiology of Pain · doi:10.1016/j.ynpai.2020.100050 · Cited by 16
Akashi, T., Noguchi, S., Takahashi, Y., Nishimura, T., & Tomi, M. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.12.028 · Cited by 8
Metadata
- Authors
- Field, M. J., Cox, P. J., Stott, E., Melrose, H., Offord, J., Su, T.-Z., Bramwell, S., Corradini, L., England, S., Winks, J., Kinloch, R. A., Hendrich, J., Dolphin, A. C., Webb, T., & Williams, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-11-14
- Volume
- 103
- Issue
- 46
- Pages
- 17537-17542
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1994334998
- Cited by
- 591
- References
- 44
- FWCI
- 19.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.